

LISTING OF THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An isolated antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:48, wherein said antibody immunospecifically binds to a respiratory syncytial virus (RSV) ~~antigen~~ F protein.

2. (Canceled)

3. (Currently Amended) An antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:20, wherein said antibody immunospecifically binds to a RSV ~~antigen~~ F protein.

4. (Canceled)

5. (Previously Presented) The antibody of claim 3 further comprising a VH domain having an amino acid sequence of SEQ ID NO:48.

6.-178. (Canceled)

179. (Currently Amended) An isolated antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a VH CDR of the antibody A4B4, wherein said antibody immunospecifically binds to a RSV ~~antigen~~ F protein.

180. (Currently Amended) An isolated antibody comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10, wherein said antibody immunospecifically binds to a RSV ~~antigen~~ F protein.

181. (Currently Amended) An isolated antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:18, wherein said antibody immunospecifically binds to a RSV ~~antigen~~ F protein.

182. (Currently Amended) An isolated antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV ~~antigen~~ F protein.

183. (Currently Amended) An isolated antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:21, wherein said antibody immunospecifically binds to a RSV antigen F protein.

184. (Currently Amended) An isolated antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV antigen F protein.

185. (Canceled)

186. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.

187. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

188. (Canceled)

189. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

190.-191. (Canceled)

192. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

193. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

194. (Canceled)

195. (Previously Presented) The antibody of claim 184, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

196.-200. (Canceled)

201. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22 and a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

202.-203. (Canceled)

204. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

205. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

206. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

207. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

208. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

209. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

210. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

211. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

212. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

213.-221. (Canceled)

222. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

223. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

224. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

225. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

226. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

227. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

228.-230. (Canceled)

231. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21.

232. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

233. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

234-240. (Canceled)

241. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

242. (Previously Presented) The antibody of claim 223, wherein antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

243. (Canceled).

244. (Previously Presented) The antibody of claim 225, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

245. (Previously Presented) The antibody of claim 226, wherein antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

246-249. (Canceled)

250. (Previously Presented) The antibody of claim 231, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

251.-260. (Canceled)

261. (Previously Presented) The antibody of claim 258, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:22.

262. (Previously Presented) The antibody of claim 258, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

263. (Previously Presented) The antibody of claim 259, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

264.-275. (Canceled)

276. (Previously Presented) The antibody of claim 198, wherein the antibody comprises:

- (a) a VL CDR1 having an amino acid sequence of SEQ ID NO:21;
- (b) a VL CDR2 having an amino acid sequence of SEQ ID NO:22; and
- (c) a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

277-279. (Canceled)

280. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184, wherein the antibody is a monoclonal antibody.

281. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184, wherein the antibody is a human antibody.

282. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184, wherein the antibody is a humanized antibody.

283. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184, wherein the antibody is a Fab fragment.

284. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184, wherein the antibody is conjugated to a therapeutic or drug moiety.

285. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184, wherein the antibody is conjugated to a detectable substance.

286. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184 and a pharmaceutically acceptable carrier.

287. (Currently Amended) The antibody of claim 1, 3, 179, 180, 181, 182, ~~or~~ 183, or 184 and instructions for use, in one or more containers.

288. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

289. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

290. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

291. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

292. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.

293. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.

294. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.

295. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:18.

296. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

297. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

298. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

299. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:19.

300.-302. (Canceled)

303. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

304. (Canceled)

305. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21, a VL CDR2 having an amino acid sequence of SEQ ID NO:22, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

306. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

307. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:21, a VL CDR2 having an amino acid sequence of SEQ ID NO:22, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

308. (Previously Presented) An isolated antibody comprising a CDR having an amino acid sequence of a VL CDR of the antibody P12F4.